143 related articles for article (PubMed ID: 35258041)
1. Infectious complications of induction treatment for acute myeloid leukaemia using the "7 + 3" protocol without antibiotic prophylaxis - 15 years of experience of one clinical site.
Cernan M; Szotkowski T; Hubacek J; Kolar M; Faber E; Indrak K; Papajik T
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2023 Sep; 167(3):236-245. PubMed ID: 35258041
[TBL] [Abstract][Full Text] [Related]
2. Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia.
Inaba H; Gaur AH; Cao X; Flynn PM; Pounds SB; Avutu V; Marszal LN; Howard SC; Pui CH; Ribeiro RC; Hayden RT; Rubnitz JE
Cancer; 2014 Jul; 120(13):1985-92. PubMed ID: 24677028
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness and safety of antibiotic prophylaxis during induction chemotherapy in children with acute leukaemia: a systematic review and meta-analysis.
Yang M; Lu X; Xin L; Luo J; Diao S; Jia Z; Cheng G; Zeng L; Zhang L
J Hosp Infect; 2023 Jun; 136():20-29. PubMed ID: 36921630
[TBL] [Abstract][Full Text] [Related]
4. Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center.
Pohlen M; Marx J; Mellmann A; Becker K; Mesters RM; Mikesch JH; Schliemann C; Lenz G; Müller-Tidow C; Büchner T; Krug U; Stelljes M; Karch H; Peters G; Gerth HU; Görlich D; Berdel WE
Haematologica; 2016 Oct; 101(10):1208-1215. PubMed ID: 27470601
[TBL] [Abstract][Full Text] [Related]
5. Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia.
Mayer K; Hahn-Ast C; Mückter S; Schmitz A; Krause S; Felder L; Bekeredjian-Ding I; Molitor E; Brossart P; von Lilienfeld-Toal M
Support Care Cancer; 2015 May; 23(5):1321-9. PubMed ID: 25617073
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia.
Boztug H; Mühlegger N; Pötschger U; Attarbaschi A; Peters C; Mann G; Dworzak M
Ann Hematol; 2017 Jan; 96(1):99-106. PubMed ID: 27699447
[TBL] [Abstract][Full Text] [Related]
7. Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients.
Caro J; Madero-Marroquin R; Zubizarreta N; Moshier E; Tremblay D; Coltoff A; Lancman G; Fuller R; Rana M; Mascarenhas J; Jacobs SE
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):903-911. PubMed ID: 36109322
[TBL] [Abstract][Full Text] [Related]
8. Moxifloxacin versus levofloxacin or ciprofloxacin prophylaxis in acute myeloid leukemia patients receiving chemotherapy.
Przybylski DJ; Reeves DJ
Support Care Cancer; 2017 Dec; 25(12):3715-3721. PubMed ID: 28660351
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic prophylaxis and the gastrointestinal resistome in paediatric patients with acute lymphoblastic leukaemia: a cohort study with metagenomic sequencing analysis.
Margolis EB; Hakim H; Dallas RH; Allison KJ; Ferrolino J; Sun Y; Pui CH; Yao J; Chang TC; Hayden RT; Jeha S; Tuomanen EI; Tang L; Rosch JW; Wolf J
Lancet Microbe; 2021 Apr; 2(4):e159-e167. PubMed ID: 34355208
[TBL] [Abstract][Full Text] [Related]
10. Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia.
Tober R; Schnetzke U; Fleischmann M; Yomade O; Schrenk K; Hammersen J; Glaser A; Thiede C; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1569-1583. PubMed ID: 35583829
[TBL] [Abstract][Full Text] [Related]
11. Clinical and microbiologic outcomes of quinolone prophylaxis in children with acute myeloid leukemia.
Felsenstein S; Orgel E; Rushing T; Fu C; Hoffman JA
Pediatr Infect Dis J; 2015 Apr; 34(4):e78-84. PubMed ID: 25764103
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis of neutropenic fever with ciprofloxacin in patients with acute myeloid leukemia treated with intensive chemotherapy.
Ghadiany M; Rahimi H; Rezvani H; Mohammad Alizadeh A; Zamani N; Mehdizadeh M; Foratyazdi M
Asia Pac J Clin Oncol; 2016 Mar; 12(1):e11-5. PubMed ID: 24330539
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic Measures During Induction for Acute Myeloid Leukemia.
McCarthy MW; Walsh TJ
Curr Oncol Rep; 2017 Mar; 19(3):18. PubMed ID: 28251490
[TBL] [Abstract][Full Text] [Related]
15. Impact of antibacterial prophylaxis during reinduction chemotherapy for relapse/refractory acute myeloid leukemia.
Ganti BR; Marini BL; Nagel J; Bixby D; Perissinotti AJ
Support Care Cancer; 2017 Feb; 25(2):541-547. PubMed ID: 27738797
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT.
Drayson MT; Bowcock S; Planche T; Iqbal G; Pratt G; Yong K; Wood J; Raynes K; Higgins H; Dawkins B; Meads D; Hulme CT; Whittaker AC; Hawkey P; Low E; Dunn JA
Health Technol Assess; 2019 Nov; 23(62):1-94. PubMed ID: 31690402
[TBL] [Abstract][Full Text] [Related]
17. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of anti-fungal but not anti-bacterial prophylaxis in intensive primary AML therapy: a real-world, retrospective comparative single-centre study.
Gerber B; Köppel J; Paul M; Nguyen-Kim TD; Frauenfelder T; Nair G; Schanz U; Manz MG
Swiss Med Wkly; 2014; 144():w13985. PubMed ID: 25055166
[TBL] [Abstract][Full Text] [Related]
19. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
Döhner H; Weber D; Krzykalla J; Fiedler W; Kühn MWM; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Fransecky L; Koller E; Wulf G; Schleicher J; Ringhoffer M; Greil R; Hertenstein B; Krauter J; Martens UM; Nachbaur D; Samra MA; Machherndl-Spandl S; Basara N; Leis C; Schrade A; Kapp-Schwoerer S; Cocciardi S; Bullinger L; Thol F; Heuser M; Paschka P; Gaidzik VI; Saadati M; Benner A; Schlenk RF; Döhner K; Ganser A;
Lancet Haematol; 2023 Jul; 10(7):e495-e509. PubMed ID: 37187198
[TBL] [Abstract][Full Text] [Related]
20. Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis.
Bainschab A; Quehenberger F; Greinix HT; Krause R; Wölfler A; Sill H; Zebisch A
Leuk Res; 2016 Mar; 42():47-51. PubMed ID: 26866663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
